Amezalpat is an investigational oral, small molecule, selective peroxisome proliferator-activated receptor-alpha antagonist.

Amezalpat has been granted FDA fast track designation as treatment for patients with hepatocellular carcinoma.

fibrolamellar hepatocellular carcinoma (FLC) mounts a ferocious attack against an unlucky few—in this case, children, adolescents, and young adults. Because its symptoms can vary from person to ...

New model predicts HCC risk in noncirrhotic chronic hepatitis B patients, improving early detection strategies.

Transarterial chemoembolization (TACE) improves survival in cirrhotic patients with hepatocellular carcinoma (HCC). The optimal schedule, best anticancer agent and best technique are still unclear.

Unresectable canine hepatocellular carcinoma (HCC) has limited nonsurgical treatment options. Sorafenib is a targeted therapy for unresectable canine HCC. However, there are limited reports on the ...

Rates and risk factors for recurrence of hepatocellular carcinoma after initial complete remission in response to transcatheter arterial chemoembolization: A systematic review and meta-analysis. This ...

Oncolytic viruses (OVs) are viruses that infect and kill cancer cells while sparing healthy tissue, making them a promising therapeutic option in cancer ...